“Among several commercial services who have claimed to be specialized to generate mouse models with genetic modifications, I recognize that Cyagen is one of the best. We are looking forward to having more cooperation with them.”Korea Brain Research Institute (KBRI)
영업일 기준 1-2일 내에 답변해 드리겠습니다.
The following is humanized models to study inflammation and allergy as well as in vivo efficacy and safety assessment of biologics and other compounds:
✔ Humanized CD4 Mice
CD4 expression in mice has a normal physiological expression and regulation mode: unaltered immune cell distribution, and T helper cell activity. This model allows in vivo efficacy and safety assessment of anti-human CD4 compound, and commonly applied in field of Inflammation, autoimmune diseases, immuno-oncology and HIV infection.
✔ Double - humanized IgE/FcεR1 Mice
The human IgE-FcεRI complex has a normal physiological expression and regulation mode. This model can be used to screen for innovative therapeutics for allergy, asthma and other IgE-mediated diseases - such as, Eosinophilic Esophagitis (EOE) and Inflammatory Bowel Disease (IBD).
✔ Humanized TNF-α Mice
Human TNF-α expression is driven by the mouse TNF-α endogenous promoter, and its expression in mice has a normal physiological expression and regulation mode. This model allows in vivo efficacy and safety assessment of anti-human TNF-α compounds in the field of autoimmune diseases and inflammation.
In 2020, Cyagen reached a strategic partnership with genOway. Founded in 1999, genOway is a leading international supplier of laboratory mice for preclinical scientific research. Cyagen is excited to introduce humanized mouse models to study inflammation and allergy as one of the selected mice product introduced in the cooperation - Why do we recommend genOway's mouse model?
1. Robust verification by both Industry leaders and literatures: Services and products from genOway have been cited many times in high-impact academic journals such as Cell, Nature, Science, and PNAS. As a partner of the the EU Research and Innovation programme (Horizon 2020), its immune checkpoint (ICP) and severe combined immunodeficient (SCID) model series have been jointly verified by the company and its partners worldwide, including leaders in the fields of immuno-oncology and immunotherapy, large pharmaceutical companies, biotechnology companies, research institutions, and more.
2. Leading supplier of genetically engineered animal models in Europe and the United States: genOway has obtained patent licenses for all its technologies used to construct models, and is the only supplier that can guarantee you the opportunity to operate all the models on your own. Founded in 1999, genOway has 21 years of experience in animal model services, the company now has developed into a leader in the field of customized, genetically modified (GM) mouse, rat, and cell model creation, while serving international pharmaceuticals (Novartis, Pfizer, BMS, Janssen, and more.) and world-famous academic research centers (National Institutes of Health (NIH), Institut Pasteur, etc.) with their services.
3. Comprehensive Intellectual Property (IP) Protection: Clear and independent IP rights are an essential facet of successful drug discovery projects. genOway provides various disease animal models with a wide range of patents and license agreements to ensure that the IP rights of the model are clear. This guarantees you freedom to operate (FTO) along with the provisions of the model.
4. Specific Model Genetic Background: All models are provided on a specific genetic strain background, of accurate and traceable sources, and includes periodic genetic testing performed in colony maintenance to ensure the reproducibility of your research results.